Reply to ‘comment on “tumour-agnostic drugs in paediatric cancers”’

Nature

Reply to ‘comment on “tumour-agnostic drugs in paediatric cancers”’"


Play all audios:

Loading...

Following our Comment on Tumour-agnostic drugs in paediatric cancers (_Br. J. Cancer_ 122:1425–1427, 2020), the National Institute for Health and Care Excellence completed its consultation


process on larotrectinib. With an improved pricing agreement, it was recommended in April 2020 for use within the Cancer Drugs Fund (CDF) for neurotrophic tyrosine receptor kinase (NTRK)


fusion-positive solid tumours in adults and children with locally advanced or metastatic disease or where surgery could cause severe health problems and no satisfactory treatment options


exist. It was recognised during the consultation that patients and clinicians may wish to access the drug earlier in treatment and that further information is required to determine optimal


positioning within the patient pathway (https://www.nice.org.uk/guidance/ta630/documents/final-appraisal-determination-document). The conditions for use associated with the CDF will allow


further real-world data collection to inform future marketing authorisation. In this issue, Oliver et al. report an interesting case of a child with infantile fibrosarcoma (IFS) with a


canonical ETV6-NTRK3 fusion who failed conventional chemotherapy, developed rapid resistance to larotrectinib and subsequently showed resistance to the second-generation TRK inhibitor


selectrectinib (Loxo-195). They elegantly map the molecular evolution of the resistance. They conclude that comparative clinical trials beyond basket studies are needed to learn when and how


to deploy drugs like larotrectinib and that until such evidence is available, cautious use of TRK inhibitors in children should be advocated. In our view, TRK inhibitors should only be used


under direct supervision by oncologists experienced in the use of such targeted agents. While agreeing that the place of larotrectinib in treatment of tumours with NTRK mutations remains to


be defined, the unusually aggressive and ultimately fatal case with incompletely resectable disease Oliver et al. present highlights the potential role for tumour-agnostic drugs like


larotrectinib to facilitate surgery or prolong life, emphasises the need to address emergent resistance mechanisms and compels us to urgently explore whether earlier use of these agents may


lead to better outcomes for patients. The level of evidence required to introduce tumour-agnostic agents such as larotrectinib into frontline treatment requires careful consideration. The


tension is to ensure equipoise in trying to design a randomised/comparative registration level trial for a heterogeneous group of tumours with a known but rare target, when a new class of


drugs with high efficacy, favourable short-term toxicity profile and an oral formulation suitable for the youngest of infants becomes available. This may be even more important for patients


likely to survive their disease, where long-term chemotherapy side effects or morbid surgical approaches may impact significantly on quality of life. IFS, a tumour of young children and the


most common paediatric malignancy harbouring an NTRK fusion, might present a more uniform population for comparative or randomised paediatric trials of TRK inhibitors. In the experience of


the European paediatric Soft tissue Sarcoma Group, only 50 cases of non-metastatic IFS were registered in 14 countries in 7 years,1 of which 19 (38%) were resected as primary treatment and


31 (62%) were Group III (macroscopic residual disease/biopsy only). Overall, 30/31 (97%) Group III patients received chemotherapy (mainly vincristine and actinomycin D, but including 5


ifosfamide, 2 cyclophosphamide and 1 doxorubicin), 2/31 patients (6%) had mutilating surgery (amputations), 1/31 (3%) was irradiated and 3/31 (10%) died (1 toxicity, 2 disease progression).


This study demonstrates that the potential population for performing prospective trials in newly diagnosed IFS is extremely small. Moreover, fatal toxicity, potential late effects of


chemotherapy, such as nephrotoxicity, reduced fertility or cardiotoxicity and the need for mutilating surgery are a real risk for these patients. The ongoing phase II study in newly


diagnosed NTRK fusion-positive IFS, solid and brain tumours and relapsed leukaemia in patients <30 years (NCT03834961) is addressing objective response rate to first-line treatment with


larotrectinib, with secondary endpoints of toxicity, event-free survival and overall survival and, for IFS, duration of response. It will provide further information on the use of the drug


in frontline and results are eagerly awaited. Meanwhile, the role of the second-generation TRK inhibitor seletrectinib is also under investigation in a phase I/II study (NCT03215511) and an


expanded access programme (NCT03206931). Additional TRK inhibitors such as entrectinib (Roche) and repotrectinib (Turning Point Therapeutics) are in development. While acknowledging the


excellent points raised by Dr. Oliver and colleagues, it remains our view that given the favourable toxicity profile compared to conventional options and the demonstrated high response


rates, TRK inhibitors constitute a highly attractive frontline option in IFS that for many patients may allow definitive, curative surgery before development of drug resistance. REFERENCE *


Orbach, D., Brennan, B., De Paoli, A., Gallego, S., Mudry, P., Francotte, N. et al. Conservative strategy in infantile fibrosarcoma is possible: the European Paediatric Soft Tissue Sarcoma


Study Group experience. _Eur. J. Cancer_ 57, 1–9 (2016). Article  Google Scholar  Download references ACKNOWLEDGEMENTS We acknowledge and thank our young patients and their families for


their willing participation in early phase clinical trials. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Paediatric and Adolescent Oncology Drug Development Team, Children and Young


People’s Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK Julia C. Chisholm, Fernando Carceller & Lynley V. Marshall Authors * Julia C. Chisholm View author


publications You can also search for this author inPubMed Google Scholar * Fernando Carceller View author publications You can also search for this author inPubMed Google Scholar * Lynley V.


Marshall View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS J.C.C., F.C. and L.V.M. all contributed to the writing, revision and approval of


this manuscript. CORRESPONDING AUTHOR Correspondence to Julia C. Chisholm. ETHICS DECLARATIONS ETHICS APPROVAL AND CONSENT TO PARTICIPATE Not applicable. CONSENT TO PUBLISH Not applicable.


DATA AVAILABILITY Not applicable. COMPETING INTERESTS J.C.C. has received consultancy fees from Bayer unrelated to the subject of this publication. L.V.M. has received speaker’s fees from


Bayer. FUNDING INFORMATION L.V.M. is supported by the Oak Foundation. J.C.C. and F.C. receive support from the Royal Marsden Cancer Charity. All authors are supported by National Health


Service funding to the National Institute for Health Research Biomedical Research Centre of The Royal Marsden Hospital. We acknowledge Experimental Cancer Medicine Centre (ECMC) funding to


our Unit. ADDITIONAL INFORMATION NOTE This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will


switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and


institutional affiliations. RIGHTS AND PERMISSIONS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,


distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and


indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit


line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,


you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS


ARTICLE CITE THIS ARTICLE Chisholm, J.C., Carceller, F. & Marshall, L.V. Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’. _Br J Cancer_ 124, 527–528 (2021).


https://doi.org/10.1038/s41416-020-01104-z Download citation * Received: 03 August 2020 * Revised: 02 September 2020 * Accepted: 07 September 2020 * Published: 01 October 2020 * Issue Date:


19 January 2021 * DOI: https://doi.org/10.1038/s41416-020-01104-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a


shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative


Trending News

The conserved microrna mir-210 regulates lipid metabolism and photoreceptor maintenance in the drosophila retina

ABSTRACT Increasing evidence suggests that miRNAs play important regulatory roles in the nervous system. However, the mo...

Remembering Louis Canelakes - The Texas Observer

As 2014 uncorks, it’s fitting and important to celebrate the enduring legacy of an extraordinary man who influenced gene...

//

// * ...Les merveilles du monde d'autrefois.... * Cri des serviteurs du palais * Nom de famille EL KABIL * Euh..les...

recycling and kitsch

* imprint * privacy policy * terms of use * cookies * copyright info * contribute * about us * contact us * newsletter *...

bdnews24.com

404 Sorry, page not found Unfortunately the page you are looking for does not existGo back to Home Page...

Latests News

Reply to ‘comment on “tumour-agnostic drugs in paediatric cancers”’

Following our Comment on Tumour-agnostic drugs in paediatric cancers (_Br. J. Cancer_ 122:1425–1427, 2020), the National...

Michael Landon - Los Angeles Times

In response to “TV Actor Michael Landon Is Dead at 54,” Part B, July 2: I was assistant to the producer of the new write...

Perceiving patterns in random series: dynamic processing of sequence in prefrontal cortex

ABSTRACT We demonstrate that regions within human prefrontal cortex develop moment-to-moment models for patterns of even...

Ectopic expression of rad52 and dn53bp1 improves homology-directed repair during crispr–cas9 genome editing

ABSTRACT Gene disruption by clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein...

Stromal modulation to prevent resistance

Access through your institution Buy or subscribe Intrinsic resistance to chemotherapy in pancreatic ductal adenocarcinom...

Top